After a couple of units of CONSIGMA™ sold to top-10 pharmaceutical companies, the first generic company has decided to invest in this innovative continuous high-shear granulation and drying technology.
The most important decision factor for this company was that CONSIGMA™ will help them reduce costs, not only in initial investment, but also in running costs. CONSIGMA™ is a small unit that can easily be installed in existing pharmaceutical production rooms, avoiding the need to invest in an expensive change or extension of the production. It requires only a minimal continuous amount of utilities and avoids energy consumption peaks. Finally, because of continuous on-line monitoring and feedback techniques, generation of out-of-spec materials is reduced to a minimum, thereby reducing the generation of toxic waste.
For more information about these and other advantages, please visit www.consigma.be or contact Collette.